Lipocine Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Unaudited consolidated results. Lipocine is a clinical-stage biopharmaceutical company developing oral drug-delivery products; it had no product-sales revenue.
Financial performance and position
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Revenue | $55,000 | $0; Q1 2023 revenue was entirely from related-party Spriaso |
| Research and development expense | $3.106 million | $1.888 million; up $1.218 million |
| General and administrative expense | $1.287 million | $1.244 million; up $44,000 |
| Operating loss | $4.339 million | $3.132 million |
| Net loss attributable to common shareholders | $3.870 million; $0.04 per share | $3.488 million; $0.04 per share |
| Interest and investment income | $370,000 | $42,000 |
| Operating cash used | $3.928 million | $3.885 million |
- At March 31, cash and cash equivalents were $4.77 million and marketable securities were $24.10 million, totaling approximately $28.87 million in unrestricted cash, equivalents and securities, versus $32.53 million at December 31, 2022.
- Investing activities provided $5.55 million, principally reflecting $12.0 million of security maturities less $6.4 million of purchases. This was portfolio turnover, not operating cash generation.
- Total liabilities were $2.06 million; the company reported no outstanding debt. The SVB loan was repaid in June 2022. Current assets were $30.61 million and current liabilities $1.93 million.
- Operating expenses exceeded revenue substantially; a revenue-based margin is not meaningful. The company reported an accumulated deficit of $187.3 million.
Material changes and business developments
- R&D expense increased 65% year over year, mainly from LPCN 1148 cirrhosis-study costs and LPCN 1154 clinical work. G&A rose modestly.
- Higher interest income and a $98,000 non-cash gain on warrant remeasurement partially offset operating losses. The comparable 2022 period included a $378,000 warrant loss and $20,000 interest expense.
- TLANDO, licensed to Antares (a Halozyme subsidiary), launched in the U.S. in June 2022. Lipocine recorded no Antares license revenue in Q1 2023 and estimated no royalty payment on Q1 TLANDO sales. Its contract asset related to Antares was $3.83 million.
- Antares terms include tiered U.S. royalties ranging from the mid-teens to 20% of net sales, potential sales milestones up to $160 million, and conditional $5 million payments in each of 2025 and 2026. These amounts are not assured.
- The board issued Series B preferred stock in March to vote on a proposed reverse stock split and related adjournment. Shares not represented at the May 10, 2023 meeting were automatically redeemed; the filing does not establish that a reverse split was completed.
- The securities class action was dismissed with prejudice on April 14, 2023. The Clarus patent litigation had been resolved under a 2021 agreement, amended in 2022.
Outlook, liquidity and risks
- Management said existing capital resources and interest were expected to fund its projected operating plan through at least May 11, 2024, including LPCN 1148 and LPCN 1154 studies and regulatory obligations. This estimate depends on assumptions and could change with study scope or costs.
- Management expects to need additional capital eventually through equity or debt financing, licensing or other arrangements. Failure to obtain funding could require delaying or reducing development and creates a risk to continued operations. The ATM offering’s registered capacity was limited to $15.7 million as of April 3, 2023; no shares were sold under it in Q1.
- Management expected LPCN 1154 pilot PK-bridge results in Q2 2023 and LPCN 1148 24-week Phase 2 results in mid-2023. A Phase 2 study for LPCN 2101 was subject to available resources. No formal revenue or earnings guidance was provided.
- Key risks include clinical and regulatory uncertainty, dependence on partners and third-party manufacturers, future financing and potential dilution, volatile share price, and Nasdaq’s $1.00 minimum-bid requirement. The filing cited a June 5, 2023 deadline to regain bid-price compliance.
- Makena was withdrawn by FDA on April 6, 2023, creating a changed competitive backdrop for LPCN 1107; further development and partnering remained uncertain.
Most important facts for investors to verify
- Cash runway assumptions, quarterly operating burn, and the timing and terms of any additional financing.
- Actual Antares TLANDO sales, royalty receipts and satisfaction of conditions for future payments and milestones.
- Reported LPCN 1154 and LPCN 1148 study results, subsequent trial plans and funding requirements.
- Nasdaq bid-price compliance and the outcome of the proposed reverse-split vote and Series B redemption process.
- Related-party Spriaso revenue and governance, as well as the status and potential dilution from outstanding options and warrants.